Facial  ||| S:0 E:7 ||| JJ
rejuvenation  ||| S:7 E:20 ||| NN
after  ||| S:20 E:26 ||| IN
intradermal  ||| S:26 E:38 ||| JJ
botulinum  ||| S:38 E:48 ||| JJ
toxin ||| S:48 E:53 ||| NN
:  ||| S:53 E:55 ||| :
is  ||| S:55 E:58 ||| VBZ
it  ||| S:58 E:61 ||| PRP
really  ||| S:61 E:68 ||| RB
the  ||| S:68 E:72 ||| DT
botulinum  ||| S:72 E:82 ||| JJ
toxin  ||| S:82 E:88 ||| NN
or  ||| S:88 E:91 ||| CC
is  ||| S:91 E:94 ||| VBZ
it  ||| S:94 E:97 ||| PRP
the  ||| S:97 E:101 ||| DT
pricks ||| S:101 E:107 ||| NN
?  ||| S:107 E:109 ||| .
The  ||| S:109 E:113 ||| DT
use  ||| S:113 E:117 ||| NN
of  ||| S:117 E:120 ||| IN
intradermal  ||| S:120 E:132 ||| JJ
botulinum  ||| S:132 E:142 ||| JJ
toxin  ||| S:142 E:148 ||| NN
A  ||| S:148 E:150 ||| DT
( ||| S:150 E:151 ||| -LRB-
onabotulinumtoxinA ||| S:151 E:169 ||| NNP
)  ||| S:169 E:171 ||| -RRB-
remains  ||| S:171 E:179 ||| VBZ
a  ||| S:179 E:181 ||| DT
relatively  ||| S:181 E:192 ||| RB
new  ||| S:192 E:196 ||| JJ
technique  ||| S:196 E:206 ||| NN
and  ||| S:206 E:210 ||| CC
is  ||| S:210 E:213 ||| VBZ
an  ||| S:213 E:216 ||| DT
off-label  ||| S:216 E:226 ||| JJ
cosmetic  ||| S:226 E:235 ||| JJ
application  ||| S:235 E:247 ||| NN
for  ||| S:247 E:251 ||| IN
facial  ||| S:251 E:258 ||| JJ
skin  ||| S:258 E:263 ||| NN
rejuvenation ||| S:263 E:275 ||| NN
.  ||| S:275 E:277 ||| .
There  ||| S:277 E:283 ||| EX
is  ||| S:283 E:286 ||| VBZ
little  ||| S:286 E:293 ||| RB
documented  ||| S:293 E:304 ||| VBN
clinical  ||| S:304 E:313 ||| JJ
evidence  ||| S:313 E:322 ||| NN
of  ||| S:322 E:325 ||| IN
the  ||| S:325 E:329 ||| DT
objective  ||| S:329 E:339 ||| JJ
benefits  ||| S:339 E:348 ||| NNS
of  ||| S:348 E:351 ||| IN
this  ||| S:351 E:356 ||| DT
therapy ||| S:356 E:363 ||| NN
.  ||| S:363 E:365 ||| .
To  ||| S:365 E:368 ||| TO
determine  ||| S:368 E:378 ||| VB
whether  ||| S:378 E:386 ||| IN
intradermal  ||| S:386 E:398 ||| JJ
facial  ||| S:398 E:405 ||| JJ
onabotulinumtoxinA  ||| S:405 E:424 ||| JJ
injection  ||| S:424 E:434 ||| NN
has  ||| S:434 E:438 ||| VBZ
any  ||| S:438 E:442 ||| DT
benefits ||| S:442 E:450 ||| NNS
.  ||| S:450 E:452 ||| .
Interventional ||| S:452 E:466 ||| NNP
,  ||| S:466 E:468 ||| ,
comparative ||| S:468 E:479 ||| JJ
,  ||| S:479 E:481 ||| ,
split  ||| S:481 E:487 ||| NN
face  ||| S:487 E:492 ||| NN
clinical  ||| S:492 E:501 ||| JJ
trial ||| S:501 E:506 ||| NN
.  ||| S:506 E:508 ||| .
Informed  ||| S:508 E:517 ||| JJ
consent  ||| S:517 E:525 ||| NN
was  ||| S:525 E:529 ||| VBD
obtained  ||| S:529 E:538 ||| VBN
from  ||| S:538 E:543 ||| IN
10  ||| S:543 E:546 ||| CD
physicians ||| S:546 E:556 ||| NNS
.  ||| S:556 E:558 ||| .
One  ||| S:558 E:562 ||| CD
half  ||| S:562 E:567 ||| NN
of  ||| S:567 E:570 ||| IN
the  ||| S:570 E:574 ||| DT
physician ||| S:574 E:583 ||| NN
's  ||| S:583 E:586 ||| POS
faces  ||| S:586 E:592 ||| NNS
were  ||| S:592 E:597 ||| VBD
randomly  ||| S:597 E:606 ||| RB
injected  ||| S:606 E:615 ||| VBN
with  ||| S:615 E:620 ||| IN
onabotulinumtoxinA  ||| S:620 E:639 ||| NNP
( ||| S:639 E:640 ||| -LRB-
2  ||| S:640 E:642 ||| CD
U ||| S:642 E:643 ||| NNP
/ ||| S:643 E:644 ||| CD
0.1  ||| S:644 E:648 ||| CD
mL ||| S:648 E:650 ||| NN
;  ||| S:650 E:652 ||| :
30  ||| S:652 E:655 ||| CD
facial  ||| S:655 E:662 ||| JJ
injections  ||| S:662 E:673 ||| NNS
on  ||| S:673 E:676 ||| IN
half  ||| S:676 E:681 ||| NN
of  ||| S:681 E:684 ||| IN
the  ||| S:684 E:688 ||| DT
face ||| S:688 E:692 ||| NN
,  ||| S:692 E:694 ||| ,
each  ||| S:694 E:699 ||| DT
0.1  ||| S:699 E:703 ||| CD
mL ||| S:703 E:705 ||| NN
)  ||| S:705 E:707 ||| -RRB-
intradermally  ||| S:707 E:721 ||| NN
and  ||| S:721 E:725 ||| CC
the  ||| S:725 E:729 ||| DT
other  ||| S:729 E:735 ||| JJ
half  ||| S:735 E:740 ||| NN
of  ||| S:740 E:743 ||| IN
the  ||| S:743 E:747 ||| DT
face  ||| S:747 E:752 ||| NN
with  ||| S:752 E:757 ||| IN
normal  ||| S:757 E:764 ||| JJ
saline  ||| S:764 E:771 ||| NNS
( ||| S:771 E:772 ||| -LRB-
30  ||| S:772 E:775 ||| CD
facial  ||| S:775 E:782 ||| JJ
injections  ||| S:782 E:793 ||| NNS
on  ||| S:793 E:796 ||| IN
half  ||| S:796 E:801 ||| NN
of  ||| S:801 E:804 ||| IN
the  ||| S:804 E:808 ||| DT
face ||| S:808 E:812 ||| NN
,  ||| S:812 E:814 ||| ,
each  ||| S:814 E:819 ||| DT
0.1  ||| S:819 E:823 ||| CD
mL ||| S:823 E:825 ||| NN
) ||| S:825 E:826 ||| -RRB-
.  ||| S:826 E:828 ||| .
The  ||| S:828 E:832 ||| DT
injecting  ||| S:832 E:842 ||| JJ
clinician  ||| S:842 E:852 ||| NN
and  ||| S:852 E:856 ||| CC
the  ||| S:856 E:860 ||| DT
subjects  ||| S:860 E:869 ||| NNS
were  ||| S:869 E:874 ||| VBD
blinded  ||| S:874 E:882 ||| VBN
to  ||| S:882 E:885 ||| TO
the  ||| S:885 E:889 ||| DT
contents  ||| S:889 E:898 ||| NNS
of  ||| S:898 E:901 ||| IN
the  ||| S:901 E:905 ||| DT
syringes ||| S:905 E:913 ||| NN
.  ||| S:913 E:915 ||| .
One  ||| S:915 E:919 ||| CD
and  ||| S:919 E:923 ||| CC
4  ||| S:923 E:925 ||| CD
weeks  ||| S:925 E:931 ||| NNS
later ||| S:931 E:936 ||| RB
,  ||| S:936 E:938 ||| ,
two  ||| S:938 E:942 ||| CD
neutral ||| S:942 E:949 ||| JJ
,  ||| S:949 E:951 ||| ,
blinded  ||| S:951 E:959 ||| JJ
observers  ||| S:959 E:969 ||| NNS
assessed  ||| S:969 E:978 ||| VBD
the  ||| S:978 E:982 ||| DT
subjects  ||| S:982 E:991 ||| NNS
in  ||| S:991 E:994 ||| IN
person ||| S:994 E:1000 ||| NN
.  ||| S:1000 E:1002 ||| .
The  ||| S:1002 E:1006 ||| DT
patients  ||| S:1006 E:1015 ||| NNS
were  ||| S:1015 E:1020 ||| VBD
also  ||| S:1020 E:1025 ||| RB
photographed  ||| S:1025 E:1038 ||| VBN
in  ||| S:1038 E:1041 ||| IN
ambient  ||| S:1041 E:1049 ||| JJ
light  ||| S:1049 E:1055 ||| JJ
surroundings  ||| S:1055 E:1068 ||| NN
and  ||| S:1068 E:1072 ||| CC
the  ||| S:1072 E:1076 ||| DT
same  ||| S:1076 E:1081 ||| JJ
observers  ||| S:1081 E:1091 ||| NNS
compared  ||| S:1091 E:1100 ||| VBN
the  ||| S:1100 E:1104 ||| DT
halves  ||| S:1104 E:1111 ||| NN
of  ||| S:1111 E:1114 ||| IN
their  ||| S:1114 E:1120 ||| PRP$
faces  ||| S:1120 E:1126 ||| NNS
in  ||| S:1126 E:1129 ||| IN
photographs  ||| S:1129 E:1141 ||| NNS
and  ||| S:1141 E:1145 ||| CC
rated  ||| S:1145 E:1151 ||| VBN
them  ||| S:1151 E:1156 ||| PRP
on  ||| S:1156 E:1159 ||| IN
a  ||| S:1159 E:1161 ||| DT
scale  ||| S:1161 E:1167 ||| NN
of  ||| S:1167 E:1170 ||| IN
-4  ||| S:1170 E:1173 ||| CD
to  ||| S:1173 E:1176 ||| TO
+4 ||| S:1176 E:1178 ||| CD
.  ||| S:1178 E:1180 ||| .
Global  ||| S:1180 E:1187 ||| JJ
improvement  ||| S:1187 E:1199 ||| NN
in  ||| S:1199 E:1202 ||| IN
skin  ||| S:1202 E:1207 ||| NN
texture  ||| S:1207 E:1215 ||| NN
and  ||| S:1215 E:1219 ||| CC
tightness  ||| S:1219 E:1229 ||| NN
was  ||| S:1229 E:1233 ||| VBD
noted  ||| S:1233 E:1239 ||| VBN
in  ||| S:1239 E:1242 ||| IN
the  ||| S:1242 E:1246 ||| DT
post-treatment  ||| S:1246 E:1261 ||| JJ
photographs  ||| S:1261 E:1273 ||| NNS
( ||| S:1273 E:1274 ||| -LRB-
the  ||| S:1274 E:1278 ||| DT
skin  ||| S:1278 E:1283 ||| NN
appeared  ||| S:1283 E:1292 ||| VBD
to  ||| S:1292 E:1295 ||| TO
be  ||| S:1295 E:1298 ||| VB
tenser  ||| S:1298 E:1305 ||| NNS
and  ||| S:1305 E:1309 ||| CC
smoother ||| S:1309 E:1317 ||| JJR
) ||| S:1317 E:1318 ||| -RRB-
,  ||| S:1318 E:1320 ||| ,
although  ||| S:1320 E:1329 ||| IN
there  ||| S:1329 E:1335 ||| EX
was  ||| S:1335 E:1339 ||| VBD
no  ||| S:1339 E:1342 ||| DT
difference  ||| S:1342 E:1353 ||| NN
between  ||| S:1353 E:1361 ||| IN
the  ||| S:1361 E:1365 ||| DT
two  ||| S:1365 E:1369 ||| CD
groups  ||| S:1369 E:1376 ||| NNS
and ||| S:1376 E:1379 ||| CC
,  ||| S:1379 E:1381 ||| ,
hence ||| S:1381 E:1386 ||| RB
,  ||| S:1386 E:1388 ||| ,
the  ||| S:1388 E:1392 ||| DT
changes  ||| S:1392 E:1400 ||| NNS
could  ||| S:1400 E:1406 ||| MD
not  ||| S:1406 E:1410 ||| RB
be  ||| S:1410 E:1413 ||| VB
clinically  ||| S:1413 E:1424 ||| RB
ascribed  ||| S:1424 E:1433 ||| VBN
to  ||| S:1433 E:1436 ||| TO
the  ||| S:1436 E:1440 ||| DT
intradermal  ||| S:1440 E:1452 ||| JJ
botulinum  ||| S:1452 E:1462 ||| JJ
toxin  ||| S:1462 E:1468 ||| NN
injections ||| S:1468 E:1478 ||| NNS
.  ||| S:1478 E:1480 ||| .
No  ||| S:1480 E:1483 ||| DT
other  ||| S:1483 E:1489 ||| JJ
meaningful  ||| S:1489 E:1500 ||| JJ
clinical  ||| S:1500 E:1509 ||| JJ
difference  ||| S:1509 E:1520 ||| NN
could  ||| S:1520 E:1526 ||| MD
be  ||| S:1526 E:1529 ||| VB
demonstrated  ||| S:1529 E:1542 ||| VBN
between  ||| S:1542 E:1550 ||| IN
the  ||| S:1550 E:1554 ||| DT
two  ||| S:1554 E:1558 ||| CD
sides  ||| S:1558 E:1564 ||| NNS
of  ||| S:1564 E:1567 ||| IN
the  ||| S:1567 E:1571 ||| DT
face ||| S:1571 E:1575 ||| NN
,  ||| S:1575 E:1577 ||| ,
in  ||| S:1577 E:1580 ||| IN
any  ||| S:1580 E:1584 ||| DT
of  ||| S:1584 E:1587 ||| IN
the  ||| S:1587 E:1591 ||| DT
10  ||| S:1591 E:1594 ||| CD
subjects ||| S:1594 E:1602 ||| NNS
,  ||| S:1602 E:1604 ||| ,
in  ||| S:1604 E:1607 ||| IN
person  ||| S:1607 E:1614 ||| NN
or  ||| S:1614 E:1617 ||| CC
in  ||| S:1617 E:1620 ||| IN
photographs ||| S:1620 E:1631 ||| NNS
.  ||| S:1631 E:1633 ||| .
The  ||| S:1633 E:1637 ||| DT
small  ||| S:1637 E:1643 ||| JJ
study  ||| S:1643 E:1649 ||| NN
sample  ||| S:1649 E:1656 ||| NN
precluded  ||| S:1656 E:1666 ||| VBN
formal  ||| S:1666 E:1673 ||| JJ
statistical  ||| S:1673 E:1685 ||| JJ
analysis ||| S:1685 E:1693 ||| NN
.  ||| S:1693 E:1695 ||| .
Intradermal  ||| S:1695 E:1707 ||| JJ
botulinum  ||| S:1707 E:1717 ||| JJ
toxin  ||| S:1717 E:1723 ||| NN
A  ||| S:1723 E:1725 ||| DT
injection  ||| S:1725 E:1735 ||| NN
does  ||| S:1735 E:1740 ||| VBZ
not  ||| S:1740 E:1744 ||| RB
appear  ||| S:1744 E:1751 ||| VB
to  ||| S:1751 E:1754 ||| TO
have  ||| S:1754 E:1759 ||| VB
any  ||| S:1759 E:1763 ||| DT
benefit  ||| S:1763 E:1771 ||| NN
in  ||| S:1771 E:1774 ||| IN
facial  ||| S:1774 E:1781 ||| JJ
rejuvenation ||| S:1781 E:1793 ||| NN
.  ||| S:1793 E:1795 ||| .
